CV-3988-a specific antagonist of platelet activating factor (PAF)

Z Terashita, S Tsushima, Y Yoshioka, H Nomura… - Life Sciences, 1983 - Elsevier
CV-3988, rac-3-(Nn-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate
was shown to be a specific inhibitor of platelet activating factor (PAF). This compound in …

Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of. omega.-pyridylalkenoic acids

K Kato, S Ohkawa, S Terao, Z Terashita… - Journal of medicinal …, 1985 - ACS Publications
Z isomers (Table I), chemical isomerization of Z isomer 10c was examined. Acid-catalyzed
isomerization of the Z isomer 10c or a mixture of E and Z … of the E and Z isomers. To examine …

Is platelet activating factor (PAF) a mediator of endotoxin shock?

ZI Terashita, Y Imura, K Nishikawa, S Sumida - European journal of …, 1985 - Elsevier
To determine whether endogenous PAF contributes to the pathogenesis of endotoxin shock,
CV-3988, a specific PAF antagonist, was injected iv to rats before, simultaneously with or …

Pathophysiological role of endothelin in acute renal failure

…, N Suzuki, A Shino, H Matsumoto, ZI Terashita… - Life sciences, 1990 - Elsevier
In conscious rats, the iv injection of endothelin (ET) caused an increase in blood urea
nitrogen (BUN), an index of renal dysfunction. In the model of acute renal failure which was …

[PDF][PDF] CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.

ZI Terashita, Y Imura, M Takatani, S Tsushima… - … of Pharmacology and …, 1987 - Citeseer
2-[N-acetyl-N-(2-methoxy-3-octadecylcarbamoyloxypropoxy-carbonyl) aminomethyl]-1-ethylpyndinium
thlonde (CV-6209) in-hibited aggregation of rabbit and human platelets induced …

Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet

ZI Terashita, Y Imura, K Nishikawa - Biochemical pharmacology, 1985 - Elsevier
The inhibitory effects of CV-3988, a specific antagonist of PAF, on the binding of [ 3 H]-PAF
to washed platelets of various species including human were examined. The dissociation …

Quinones. 4. Novel eicosanoid antagonists: synthesis and pharmacological evaluation

…, K Kato, S Terao, Y Ashida, Z Terashita… - Journal of medicinal …, 1989 - ACS Publications
A new series of m-phenyl-cv-quinonylalkanoic acids and related compounds was synthesized.
The compounds were tested fortheir inhibitory effects on U-44069-induced contraction of …

Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1, 3, 4-trisubstituted 2-oxopiperazine derivatives …

…, T Miyawaki, Y Imai, Z Terashita… - Journal of medicinal …, 1998 - ACS Publications
Based on the lead tetrapeptide RGDF, two possible non-peptide glycoprotein (GP) IIb-IIIa
antagonists possessing an (S)-2-oxopiperazine-3-acetic acid moiety as a scaffold …

Orally active GPIIb/IIIa antagonists: synthesis and biological activities of masked amidines as prodrugs of 2-[(3S)-4-[(2S)-2-(4-amidinobenzoylamino)-3-(4 …

…, T Miyawaki, M Kawamura, Z Terashita… - Chemical and …, 2001 - jstage.jst.go.jp
… Hydrogenolysis of 5 in the presence of 10% Pd–C to remove the benzyloxycarbonyl (Z) …
,b Toshio MIYAWAKI,a Masaki KAWAMURA,c Zen-ichi TERASHITA,c and Takehiko NAKA a …

Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.

Z Terashita, M Kawamura, M Takatani… - … of Pharmacology and …, 1992 - ASPET
Pharmacological profiles of a novel specific platelet activating factor (PAF) antagonist, TCV-309
(3-bromo-5-[N-phenyl-N-[2-[2- (1,2,3,4-tetrahydro-2-isoquinolycarbonyloxy)ethyl] …